SecBot SecBot
SECBOTREPLAY Home › Report › ORIC

ORIC · ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus…

ORIC Pharmaceuticals · PRESS-RELEASE filed Aug 3, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Aug 3, 2026 at 16:05 ET

ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus of $(0.36) by $0.02. The operational highlight is the initiation of Himalayas-1, a global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer, and a clinical collaboration with Bayer for darolutamide supply. Cash runway extends into 2H 2028, with key data catalysts expected in 2H 2026.

  • Q2 2026 net loss $(0.38)/share vs consensus $(0.36), a -5.6% miss
  • Initiated global Phase 3 registrational trial Himalayas-1 for rinzimetostat in mCRPC
  • Entered clinical trial collaboration with Bayer to receive darolutamide at no cost for Himalayas-1
  • Cash and investments $387.6M, expected runway into 2H 2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access